<DOC>
	<DOCNO>NCT01782508</DOCNO>
	<brief_summary>The purpose study compare relapse free survival overall survival Imatinib ( Gleevec ) high dose Interferon ( Intron ) treat melanoma primary tumor regional lymphonode ( ) remove patient whose disease carry c-kit mutation . It assume Gleevec may effective relapse free survival adjuvant treatment compare Interferon .</brief_summary>
	<brief_title>A Phase II Study Imatinib Versus Interferon Adjuvant Therapy KIT-mutated Melanoma</brief_title>
	<detailed_description>If mutation test show patient eligible choose participate study , randomize receive imatinib/Interferon . Each imatinib pill 100mg participant take 4 pill daily ( 400mg ) .Participants randomize interferon arm receive Interferon 1500wiu/m2 d1-5 4 week follow 900wiu IH TIW 11 month . The follow study procedure also perform routine interval throughout course treatment include blood test , medical history update , physical exam Chest/Abdomen/Pelvic CT examinations.Participants study one year follow relapse distal metastasis .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Melanoma patient whose primary tumor regional lymphonodes ( ) resect Histologically document AJCC stage IIB IIIC Ckit mutation document either primary metastatic lymphnode site ECOG performance status 0 1 Age 18 year old Creatinine &lt; 1.5 x ULN ANC &gt; 1500 ul Platelets &gt; 100,000 ul Total bilirubin , AST , ALT &lt; 2 x ULN Amylase lipase &lt; 1.5 x ULN prior chemotherapy investigational drug Severe and/or uncontrolled medical disease Pregnant nursing mother Any significant medical , surgical , psychiatric condition may interfere compliance Patient &lt; 5 year free another primary malignancy except : basal cell skin cancer cervical carcinoma situ Concurrent treatment Warfarin Prior treatment ckit inhibitor Patient Grade III/IV cardiac problem define NYHA criterion No H2 blockers proton pump inhibitor Known chronic liver disease Known diagnosis HIV infection Major surgery within 2 week prior study entry Patient receive investigational agent within 28 day first study drug dose Chemotherapy within 4 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>melanoma , adjuvant therapy , kit mutate melanoma</keyword>
</DOC>